~~<i id='8996AA6FC6'><strike id='8996AA6FC6'><tt id='8996AA6FC6'><pre id='8996AA6FC6'></pre></tt></strike></i>~~

Home» explore» hotspot

hotspot

author：comprehensive 2025-09-27 15:07:30 Page View：9

Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Pregnancy ages women, but effects reverse after delivery
Next article： Sports medicine is finally prioritizing gender equality

explore

Wildfire smoke exposes gaps in outdoor worker protections

ApersonwaitingforthesubwaywearsafilteredmaskassmokyhazefromwildfiresinCanadablanketsaneighborhoodinN

Yancopoulos of Regeneron works to expand Dupixent success

GeorgeYancopoulosonthe2024BreakthroughSummitEaststageSTATGeorgeYancopoulosisintouchwithhisteenagesel

Novavax promises a turnaround & Lilly roils the obesity market

SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We

Researchers separate signal from noise in heart wearable data

AdobeAswearablehealthdevicesgrowmorepopularintheU.S.,there’sagrowingopportunitytotrackthebroaderadul